≥5
medicines = Polypharmacy
≥10
medicines = Excessive Polypharmacy
50%
of adults >65 take ≥5 medicines
25%
of adults >65 take ≥10 medicines
Definition
Polypharmacy
The concurrent use of 5 or more medicines by a patient. Commonly defined as a numerical threshold but context is essential — the appropriateness of each medicine matters.
Excessive Polypharmacy
The concurrent use of 10 or more medicines. Associated with exponentially higher risk of adverse drug reactions, interactions, and non-adherence.
The Prescribing Cascade
When a drug side effect is misidentified as a new condition and treated with another drug, creating a chain of inappropriate prescribing. Example: NSAID → hypertension → antihypertensive added → ankle oedema → diuretic added.
Appropriate vs Problematic
Appropriate Polypharmacy
Multiple medicines are clinically justified when a patient has complex multimorbidity and each medicine is evidence-based, achieving agreed treatment goals without causing undue harm.
- Example: post-MI patient on aspirin, statin, beta-blocker, ACEi, and eplerenone
- Each medicine has clear indication and benefit
- Regularly reviewed and aligned with patient goals
Problematic Polypharmacy
When medicines are prescribed without adequate justification, or the combination creates cumulative harm exceeding benefit:
- Cumulative side effects and drug–drug interactions
- Prescribing cascade (treating side effects with more drugs)
- High treatment burden reducing quality of life
- Medicines no longer aligned with patient's goals of care
Harms of Problematic Polypharmacy
Safety Harms
- Falls & fractures — sedatives, antihypertensives, diuretics
- Cognitive impairment — anticholinergics, benzodiazepines, opioids
- ADRs cause 6–17% of hospital admissions in elderly patients
- Renal impairment from nephrotoxic drug accumulation
- GI bleeding (NSAID + anticoagulant combinations)
Adherence & Burden
- Non-adherence rises sharply above 5 medicines
- Complex regimens increase pill burden and confusion
- Financial toxicity — cost of multiple prescriptions
- Time burden: multiple GP/clinic visits for monitoring
- Reduced quality of life from side effect management
System-Level Harms
- Inappropriate prescribing cascade perpetuated
- Hospital admissions from preventable ADRs
- Duplicated prescribing from multiple specialists
- Lack of coordinated medication review
- OTC & supplement interactions undetected
GCC Context
The Gulf Cooperation Council (UAE, Saudi Arabia, Qatar, Kuwait, Bahrain, Oman) faces distinct polypharmacy challenges:
Healthcare System Factors
- Multiple specialist consultations in fragmented private healthcare systems, each prescribing independently
- No unified medication record across providers until recently (DHA/HAAD developing integrated records)
- OTC medicine availability without prescription in some GCC pharmacies
- Self-medication culture and cross-border medicine purchase
Patient & Cultural Factors
- Herbal and traditional medicine use frequently unreported
- Ramadan fasting significantly alters medication timing and adherence
- High rates of type 2 diabetes, hypertension, and dyslipidaemia increase polypharmacy burden
- Language barriers in expatriate populations may affect medication understanding
Treatment Burden Concept
Treatment burden is the workload of healthcare imposed on patients and the impact it has on their functioning and wellbeing. It is distinct from symptom burden.
Components of Treatment Burden
- Taking and managing medicines (timing, storage, administration)
- Monitoring and self-testing requirements
- Attending multiple appointments and follow-ups
- Navigating healthcare systems and insurance
- Dietary restrictions and lifestyle modifications
- Financial costs of medicines and healthcare visits
Nurses can assess treatment burden using validated tools such as the Treatment Burden Questionnaire (TBQ) or the Multimorbidity Treatment Burden Questionnaire (MTBQ). High treatment burden is associated with non-adherence, poorer outcomes, and reduced quality of life.
STOPP/START v3 (Screening Tool of Older Persons' Prescriptions / Screening Tool to Alert to Right Treatment) — validated screening criteria for potentially inappropriate prescribing in adults aged ≥65. Updated v3 published 2023.
STOPP v3 — Medicines to Consider Stopping
Medicines that may cause more harm than benefit in older adults in the specified circumstances
| Drug/Class | Condition/Context | Risk |
|---|---|---|
| Anticholinergic drugs (TCAs, antihistamines, bladder antimuscarinics, antipsychotics) | Cognitive impairment or dementia | High Worsens cognition, delirium risk |
| Benzodiazepines (diazepam, lorazepam, temazepam) | Falls risk, frailty, age >65 | High Falls, fractures, sedation |
| NSAIDs (ibuprofen, naproxen, diclofenac) | Heart failure OR eGFR <50 mL/min | High Fluid retention, renal failure |
| NSAIDs | With anticoagulants/antiplatelet agents | High GI bleeding risk ×4 |
| PPI (proton pump inhibitor) | No evidence-based indication for >8 weeks | Moderate C. diff, hypomagnesaemia, fractures |
| PPIs routinely | With aspirin or clopidogrel without high GI risk | Moderate Overuse; stop unless peptic ulcer history/high GI risk |
| Antipsychotics (haloperidol, risperidone, quetiapine) | BPSD in dementia (behavioural/psychological symptoms) | High Stroke risk ×3, mortality increase |
| Tricyclic antidepressants (TCAs) | Constipation | High Anticholinergic burden worsens constipation |
| Digoxin | Atrial fibrillation as first-line rate control | Moderate Preferred: beta-blocker or CCB |
| Loop diuretics | Dependent ankle oedema alone (no cardiac/renal cause) | Moderate Electrolyte imbalance, falls |
| Z-drugs (zopiclone, zolpidem) | Insomnia in older adults | High Falls, cognitive impairment |
| Sulphonylureas (long-acting) (glibenclamide, glimepiride) | Type 2 diabetes in frail/elderly | High Prolonged hypoglycaemia risk |
| Opioids (regular) | With concurrent benzodiazepine | High Respiratory depression, death |
| Systemic corticosteroids | As long-term monotherapy for RA or OA | High Without bone protection — fracture risk |
START v3 — Medicines to Consider Starting
Evidence-based treatments that are commonly omitted in older adults with established conditions
| Drug/Class | Indication | Notes |
|---|---|---|
| ACE inhibitor / ARB | Heart failure with reduced ejection fraction (HFrEF) / post-MI | Start Mortality benefit; monitor U&E/creatinine |
| Beta-blocker | Stable heart failure / post-MI / rate control in AF | Start Mortality benefit in HF |
| Statin | Established cardiovascular disease (CVD) | Start Unless limited life expectancy or patient preference |
| Anticoagulation | Non-valvular AF with CHA₂DS₂-VASc ≥2 | Start Stroke prevention; DOAC preferred in most |
| Antiplatelet (aspirin/clopidogrel) | Established ischaemic CVD | Start Secondary prevention |
| Bone protection (bisphosphonate + calcium/vitamin D) | On systemic corticosteroids >3 months | Start FRAX score if uncertain |
| Vitamin D | Housebound, limited sun exposure, nursing home resident | Start Falls and fracture prevention |
| Inhaled SABA/LABA + ICS | Persistent symptomatic asthma or COPD | Start If not already prescribed despite symptoms |
| Metformin | Type 2 diabetes (if eGFR ≥30 and not contraindicated) | Start First-line; cardioprotective |
| PDE5 inhibitor / referral | Erectile dysfunction in diabetes or CVD | Consider QoL benefit; check for nitrate use (contraindicated) |
Anticholinergic Burden
Multiple medicines with anticholinergic properties have cumulative cognitive effects. Assessed using the Anticholinergic Cognitive Burden (ACB) scale.
High ACB Medicines (score 3)
- Amitriptyline, imipramine (TCAs)
- Oxybutynin, tolterodine (bladder)
- Chlorphenamine (antihistamine)
- Olanzapine, clozapine (antipsychotics)
- Paroxetine (SSRI with high ACB)
Moderate ACB Medicines (score 2)
- Cetirizine, loratadine
- Loperamide
- Codeine, tramadol
- Carbamazepine
- Quetiapine, haloperidol
ACB total score ≥3 is associated with increased dementia risk and cognitive decline. Review and reduce anticholinergic burden proactively in all older adults.
Structured Medication Review (SMR)
Defined by NICE NG5 (Multimorbidity guideline): a clinical review of all medicines by a healthcare professional with the patient, to optimise treatment and ensure medicines meet the patient's goals.
When Indicated
- Annually for patients on ≥10 medicines
- Patients with multimorbidity taking ≥5 medicines
- Significant change in renal function or frailty
- Following hospital admission
- Patient or carer request
- Suspected ADR or new symptom (possible prescribing cascade)
Who Conducts
- Pharmacist-led: detailed clinical medication review, STOPP/START application
- GP-led: integrated with care planning
- Nurse-facilitated: nurses identify need, facilitate Brown Bag review, coordinate referral
Brown Bag Medication Review
Patient brings all medicines (including OTC, supplements, herbal remedies, inhalers, patches, eye drops) in a bag for comprehensive review.
Process
- Invite patient to collect all medicines from home
- List every item including OTC and supplements
- Compare against GP/specialist prescription records
- Identify discrepancies, expired medicines, duplications
- Assess understanding of purpose and correct use
- Review adherence (pill counts, dosette box inspection)
- Refer for formal medication review if issues identified
GCC relevance: Particularly important to ask about herbal medicines, ginseng, garlic supplements, gingko biloba, and St John's Wort — all common in GCC populations and frequently unreported.
Medicines Reconciliation on Admission
NICE NG5 recommends medicines reconciliation within 24 hours of hospital admission. The goal is to ensure continuity and prevent errors at care transitions.
Step 1: Gather Information
- GP repeat prescription list
- Community pharmacy dispensing history
- Patient/carer account (including OTC/supplements)
- Previous discharge summaries
- Specialist clinic letters
Step 2: Reconcile
- Compare all sources for discrepancies
- Identify medicines omitted, duplicated, or at wrong dose
- Document intentional vs unintentional changes
- Communicate discrepancies to prescriber
- Update medication record
Step 3: Communicate
- Document reconciled list clearly in patient notes
- Ensure accurate discharge prescription
- Discharge summary includes all medication changes
- Communicate with GP/community pharmacy on discharge
- Patient/carer education on any changes
Medicines Optimisation (NICE)
NICE defines medicines optimisation around 4 principles:
- Aim to understand the patient's experience — what matters to the patient, their beliefs and concerns about medicines
- Evidence-based choice of medicines — use best available evidence aligned with patient values
- Ensure medicines use is as safe as possible — systems to reduce harm at all stages
- Make medicines optimisation part of routine practice — regular review integrated into care
Medication Therapy Management (MTM)
US-origin model increasingly adopted in GCC pharmacy practice. Provides a structured, patient-centred service including:
- Comprehensive Medication Review (CMR) — complete assessment of all medicines
- Targeted Medication Review (TMR) — focused review of specific issues
- Personal Medication Record (PMR) provided to patient
- Medication Action Plan (MAP) with agreed goals
- Referral or prescriber consultation as needed
- Documentation and follow-up
Shared Decision Making in Deprescribing
Stopping or reducing medicines requires genuine shared decision making — not just informing the patient, but exploring values and preferences.
Key Nursing Role
- Identify patient concerns about stopping medicines ("will my condition get worse?")
- Explore what matters most to the patient (quality of life vs longevity)
- Explain risk/benefit in plain language
- Support patient to voice preferences to prescriber
- Monitor after deprescribing and escalate concerns
Communication Approach
- Validate concerns: "It makes sense you're worried about stopping this"
- Reframe stopping positively: "We're choosing the medicines that help most"
- Use trial language: "Let's try stopping for 4 weeks and see how you feel"
- Empower: "You can restart if needed — this is your choice"
- Document discussion and patient decision clearly
What is Deprescribing?
Deprescribing is the planned and supervised process of reducing or stopping medicines where the potential harms outweigh the potential benefits, in the context of an individual patient's goals of care, level of functioning, life expectancy, and preferences.
Deprescribing is an active, positive therapeutic intervention — not a sign of giving up. It requires the same clinical rigour as prescribing.
Triggers for Deprescribing Review
- Falls or near-miss — identify falls-risk medicines
- New cognitive decline — anticholinergic burden, sedatives
- Renal impairment — eGFR drop below thresholds
- Patient or carer request — side effects, pill burden, cost
- Change in goals of care — palliative transition, frailty
- Palliative/end-of-life care — preventive medicines no longer appropriate
- Swallowing difficulties — review need for all oral medicines
- Admission to care home — comprehensive review opportunity
- Significant weight loss or frailty progression
- ADR identified — prescribing cascade review
Which Medicines to Deprescribe First
Highest Priority
- Highest harm:benefit ratio for this patient
- Falls-risk medicines in patients who have fallen
- Anticholinergic drugs in cognitive impairment
- Medicines for primary prevention in limited life expectancy
- Statins in life expectancy <1 year or advanced dementia
- Antihypertensives if BP consistently low or patient symptomatic
Lower Priority (but important)
- Medicines without clear indication or diagnosis documented
- Medicines unchanged for >2 years without review
- Duplicate agents (two PPIs, two laxatives)
- Preventive medicines when benefit horizon exceeds life expectancy
Deprescribing Frameworks
TREAT Framework
Target — identify the medicine(s) to review
Review — current indication, benefit, and harm
Evidence — what does the evidence say at this stage?
Action — stop, reduce, switch, or continue
Track — monitor for rebound, withdrawal, clinical change
Garfinkel Algorithm
A structured tool for deprescribing in elderly. For each medicine ask:
- Is this medicine essential for the patient's survival?
- Does this medicine improve QoL significantly?
- Does the treatment goal apply given life expectancy?
- Does the patient wish to continue this medicine?
- Is the dose the lowest effective dose?
If majority answered No → candidate for deprescribing. Validated in nursing home populations.
Gradual Reduction vs Abrupt Stop
| Drug Class | Approach | Rationale |
|---|---|---|
| Benzodiazepines | Gradual taper — 10–25% every 1–4 weeks | Withdrawal seizures, rebound anxiety, autonomic instability |
| Opioids (long-term) | Gradual taper — reduce by 10–20% weekly | Withdrawal syndrome: pain, agitation, GI symptoms |
| Antidepressants (SSRIs/SNRIs) | Gradual taper — weeks to months | Discontinuation syndrome: flu-like, electric shock sensations |
| Beta-blockers | Gradual taper — over 2–4 weeks | Rebound tachycardia, angina, hypertension |
| Corticosteroids (long-term) | Gradual taper — HPA axis suppression risk | Adrenal insufficiency if stopped abruptly |
| Statins | Can stop abruptly in appropriate cases | No withdrawal syndrome; monitor lipids if primary prevention concern |
| PPIs | Step down or alternate day | Rebound acid hypersecretion if stopped abruptly — step down first |
| Antihypertensives | Gradual reduction preferred | Rebound hypertension; monitor BP closely |
| Anticoagulants | Shared decision required | Thromboembolic risk; clear clinical indication for stopping needed |
Patient Communication About Stopping Medicines
Validate Concerns
- Acknowledge the patient has taken this medicine for a long time
- Validate their worry that symptoms may return
- Recognise the trust placed in the original prescriber
- Do not dismiss previous prescribing decisions
Explain the Rationale
- Be honest about why the benefit:risk has changed
- Use patient-friendly language (avoid jargon)
- Show empathy — stopping is sometimes harder than starting
Trial Discontinuation
- Frame as a trial: "Let's try without it for 4–8 weeks"
- Agree on symptoms to watch for and when to seek help
- Offer a safety net: can restart if needed
- Book follow-up to review
Monitor for Rebound
- Document date of deprescribing decision
- Review at 4–8 weeks — sooner if high-risk
- Note any new symptoms that may be withdrawal vs disease return
- Distinguish withdrawal from disease relapse clinically
High-Risk Medicines require structured, scheduled monitoring to detect toxicity, organ damage, or treatment failure early. Nurses play a central role in ensuring monitoring is completed and escalating abnormal results.
Monitoring Requirements by Medicine
| Medicine | Parameters to Monitor | Frequency | Key Thresholds / Actions |
|---|---|---|---|
| Warfarin | INR (International Normalised Ratio) | Weekly until stable, then every 4–6 weeks when stable | Target INR 2–3 (AF, DVT/PE) or 2.5–3.5 (mechanical heart valve). INR >5 → hold and review; INR >8 or bleeding → urgent review |
| Methotrexate | FBC (full blood count), LFTs, U&E, creatinine | Monthly for first 6 months → every 2–3 months when stable | Must have folic acid 5mg once weekly prescribed (not on same day as methotrexate). Withhold if WBC <3.0 or platelets <100. LFTs ×2 normal → dose review |
| Lithium | Serum lithium levels, TSH, U&E, eGFR/creatinine | Levels every 3–6 months when stable; TSH/U&E every 6 months | Target range 0.4–1.0 mmol/L (maintenance). >1.5 mmol/L → toxicity risk (nausea, tremor, ataxia, confusion). Check level 12h post-dose |
| Amiodarone | TFTs (thyroid function — TSH, T3, T4), LFTs, CXR, eye exam | TFTs and LFTs every 6 months; CXR annually; eye exam annually | Causes hypo- and hyperthyroidism (iodine-rich). Pulmonary toxicity (rare but serious — new breathlessness → CXR urgently). Corneal microdeposits (95%) — usually benign |
| Digoxin | Serum digoxin levels, U&E, renal function (creatinine) | Levels if toxicity suspected; U&E regularly (renal monitoring) | Therapeutic range 0.5–2.0 nmol/L. Hypokalaemia dramatically increases toxicity risk — check K+ before each level. Toxicity: nausea, visual disturbance (yellow/green halos), bradycardia, heart block |
| Metformin | eGFR (renal function), B12 levels (long-term use) | eGFR annually (more frequent if declining renal function) | Withhold if eGFR <30 mL/min/1.73m². Reduce dose if eGFR 30–45. Risk of lactic acidosis if given in severe renal impairment. Check B12 every 1–2 years (causes deficiency) |
| ACE inhibitors / ARBs | U&E (potassium, sodium), creatinine / eGFR, blood pressure | 1–2 weeks after starting/dose increase; then every 3–6 months | Rise in creatinine ≤30% acceptable. >30% rise → hold and renal review. Hyperkalaemia (K+ >5.5) → stop; Hypotension — especially in dehydration |
| NSAIDs | Blood pressure, renal function (U&E/creatinine), GI symptoms | Baseline then review at 1–4 weeks; ongoing if long-term use | Avoid in eGFR <50, heart failure, concurrent anticoagulant. Always co-prescribe PPI if aged >65 or high GI risk. Short-term use preferred |
| Antipsychotics (olanzapine, risperidone, quetiapine, aripiprazole) |
Weight/BMI, fasting glucose/HbA1c, fasting lipids, BP, ECG (QTc) | Baseline, then at 3 months, then annually. Weight monthly initially | Metabolic syndrome risk. QTc >500ms → cardiology review. Weight gain >7% baseline → urgent review. Annual ECG recommended. Extra-pyramidal side effects: review dose |
| Clozapine | FBC (mandatory — agranulocytosis monitoring), metabolic panel, ECG | Weekly FBC for 18 weeks → fortnightly → 4-weekly (CPMS/ZAPIA register) | Neutrophils <3.0×10⁹/L → amber alert; <2.0 → red alert → stop immediately. Registered in Clozapine Patient Monitoring Service (CPMS). Myocarditis risk in first month — monitor troponin |
Nursing Monitoring Responsibilities
Before Administering
- Confirm monitoring is up to date
- Check blood results are within acceptable range
- Withhold if specified thresholds breached
- Document reasoning if withheld
- Alert prescriber to abnormal results
During Administration
- Observe for acute adverse reactions
- Monitor vital signs as required
- Document administration accurately
- Assess patient-reported symptoms
- Ensure correct timing (e.g. methotrexate weekly)
Ongoing Monitoring
- Arrange or request blood tests per schedule
- Document monitoring in care plan/notes
- Educate patient on signs of toxicity
- Coordinate with pharmacist and prescriber
- Ensure monitoring intervals not missed
Key Drug Interactions to Know
| Combination | Risk | Action |
|---|---|---|
| Warfarin + NSAIDs / aspirin | Major bleeding risk | Avoid or use with extreme caution; increase INR monitoring |
| ACEi/ARB + potassium-sparing diuretic | Severe hyperkalaemia | Monitor K+ closely; avoid triple whammy (ACEi + diuretic + NSAID) |
| Methotrexate + NSAIDs | Methotrexate toxicity (reduced renal clearance) | Avoid concurrent use |
| Lithium + NSAIDs / thiazides | Elevated lithium levels → toxicity | Monitor levels; avoid NSAIDs; caution with diuretics |
| Amiodarone + warfarin | Doubles INR — major bleeding risk | Halve warfarin dose when starting amiodarone; very frequent INR monitoring |
| St John's Wort + any medicine | Induces CYP450 — reduces levels of warfarin, digoxin, antiepileptics, antiretrovirals, oral contraceptives | Discontinue St John's Wort; review all affected medicines |
GCC-Specific Polypharmacy Challenges
Healthcare System Issues
- Multiple specialist prescribing: patients in GCC private healthcare frequently see multiple specialists (cardiologist, endocrinologist, nephrologist, rheumatologist) each prescribing independently, without a coordinating primary care physician
- No unified medication record: historically no shared EHR across facilities — now being developed through DHA (Dubai Health Authority) and HAAD/DOH (Health Authority Abu Dhabi / Department of Health)
- OTC availability: many medicines available without prescription at GCC pharmacies contributing to self-treatment and unrecognised polypharmacy
- Pharmacist-led review developing: DHA and DOH are developing pharmacist-led medication review services aligned with UK/international models
Patient & Cultural Context
- Herbal/traditional medicine: ginseng, garlic supplements, gingko biloba, black seed (Nigella sativa), and Hamdard preparations commonly used and frequently not reported to healthcare providers
- St John's Wort: used for low mood; critical interactions with warfarin, digoxin, antiepileptics, antidepressants, HIV medicines — nurses must ask specifically
- Ramadan fasting: fasting from dawn to sunset requires complete re-timing of medication schedules — insulin, antidiabetics, antihypertensives, and anticoagulants all need adjustment; nurses should initiate Ramadan medication review proactively in Feb/March
- Language diversity: large expatriate populations (South Asian, Southeast Asian, Western) may have limited Arabic or English, affecting medication literacy
Herbal Medicine Interactions in GCC Practice
| Herb / Supplement | Common Use | Key Drug Interactions | Mechanism |
|---|---|---|---|
| St John's Wort (Hypericum) | Low mood, anxiety | Warfarin, digoxin, ciclosporin, antiepileptics, SSRIs, OCP, HIV drugs | Potent CYP3A4 and P-glycoprotein inducer → reduces drug levels significantly |
| Ginseng | Energy, immune boost | Warfarin (reduced anticoagulation), diabetes medicines (hypoglycaemia), MAOIs | Antiplatelet effects; variable CYP effects |
| Garlic supplements | Cardiovascular health | Warfarin, antiplatelet agents (increased bleeding), antihypertensives (additive BP reduction) | Antiplatelet and anticoagulant properties |
| Gingko biloba | Memory, cognition | Warfarin, aspirin, NSAIDs, SSRIs (bleeding risk), antiepileptics | Inhibits platelet activating factor; possible CYP2C9 induction (reduces warfarin) |
| Black seed / Nigella sativa | Immunity, diabetes, respiratory | Cyclosporin, warfarin, antihypertensives, antidiabetics | Multiple mechanisms; widely used in GCC and Middle East populations |
Ramadan Medication Management
Medicines Requiring Review
- Insulin: significant dose and timing adjustment needed; Type 1 diabetics at high hypoglycaemia risk
- Oral antidiabetics: sulphonylureas (high hypoglycaemia risk — consider stopping/dose reduction); metformin (retiming to Iftar/Suhoor)
- Antihypertensives: retiming; once-daily at Iftar often suitable
- Anticoagulants (warfarin/DOACs): timing relative to meals critical; INR may be affected by dietary changes during Ramadan
- Diuretics: avoid during fasting hours if possible — dehydration risk; review timing
Nursing Actions
- Identify Muslim patients on high-risk medicines before Ramadan
- Facilitate pre-Ramadan medication review (at least 4–6 weeks before)
- Educate patients on hypoglycaemia recognition and when to break fast (blood glucose <4 mmol/L)
- Document Ramadan medication plan in care record
- Advise increased glucose monitoring, especially Type 1 diabetics
- Refer high-risk patients (Type 1 DM, chronic kidney disease, cardiac patients) to physician for individualised plan
DHA / DOH / SCFHS Exam Preparation
STOPP/START — Key Exam Points
- STOPP = medicines to consider stopping in older adults
- START = medicines that should be started but are often omitted
- Anticholinergics + cognitive impairment = STOPP
- Benzodiazepines + falls = STOPP
- NSAIDs + heart failure or eGFR <50 = STOPP
- Antipsychotics + dementia = STOPP (stroke risk ×3)
- ACEi/ARB + post-MI or HFrEF = START
- Statin + CVD (if life expectancy permits) = START
- Anticoagulation + AF with CHA₂DS₂-VASc ≥2 = START
- Vitamin D + housebound elderly = START
Medication Reconciliation Exam Points
- NICE NG5: reconciliation within 24 hours of admission
- Three sources must be compared: GP list, dispensing history, patient account
- Include OTC medicines, supplements, inhalers, eye drops, patches
- Methotrexate: MUST have folic acid co-prescribed
- Warfarin: target INR 2–3 (standard) or 2.5–3.5 (metal valve)
- Lithium: level 0.4–1.0 mmol/L; checked 12h post-dose
- Clozapine: mandatory CPMS registration and weekly bloods (18 weeks)
- Metformin: withhold if eGFR <30
High-Risk Drug Monitoring Summary
| Drug | Key Test | Frequency |
|---|---|---|
| Warfarin | INR | 4–6 weekly (stable) |
| Methotrexate | FBC + LFTs | Monthly → 3-monthly |
| Lithium | Levels + TSH + U&E | 6-monthly |
| Amiodarone | TFTs + LFTs + CXR | 6-monthly + annual |
| Clozapine | FBC (mandatory) | Weekly → fortnightly → 4-weekly |
| Metformin | eGFR | Annually |
| ACEi/ARB | U&E + creatinine | 1–2wk after start, then 3-monthly |
| Antipsychotics | Metabolic + ECG | 3 months, then annually |
GCC Exam Specific Points
- DHA: Dubai Health Authority — regulates healthcare in Dubai emirate; DHPO (Dubai Health Platform/Online) developing shared records
- DOH/HAAD: Department of Health Abu Dhabi — regulates health services in Abu Dhabi; setting medicines reconciliation standards
- SCFHS: Saudi Commission for Health Specialties — licenses nurses in Saudi Arabia; pharmacology is a key exam domain
- MOH UAE: Ministry of Health and Prevention — federal regulation; coordinates with DHA/DOH
- Polypharmacy is a listed patient safety concern in GCC National Patient Safety Goals
- Herbal medicine interactions: St John's Wort is the highest-yield herbal interaction for exams
Common Exam Scenarios
Scenario 1
An 80-year-old woman with dementia is prescribed haloperidol for agitation. What should the nurse flag?
Answer: STOPP criteria — antipsychotics in dementia carry 3× increased stroke risk and increased mortality. Flag for deprescribing review; explore non-pharmacological behavioural strategies first.
Scenario 2
A patient on warfarin for AF mentions they have been taking St John's Wort for low mood for 2 months. Their INR is 1.4 (subtherapeutic).
Answer: St John's Wort induces CYP3A4 — reduces warfarin levels → subtherapeutic INR → stroke risk. Stop St John's Wort immediately; increase INR monitoring; refer for mood review and appropriate treatment.
Scenario 3
Patient on methotrexate 15mg weekly presents with mouth ulcers, nausea, and FBC shows WBC 2.1.
Answer: Methotrexate toxicity/bone marrow suppression. WBC <3.0 → withhold immediately. Check if folic acid is co-prescribed (often omitted). Urgent medical review. Report as potential adverse drug reaction.
Scenario 4
A 75-year-old man with hypertension, diabetes, and HFrEF is not on an ACE inhibitor. What does START criteria recommend?
Answer: START — ACEi should be prescribed for HFrEF. Evidence-based mortality benefit. Flag for prescriber review. Also ensure beta-blocker prescribed if not contraindicated.